


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A particle consisting of a solid dispersion, comprising:

- (a) a compound of formula



a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof,

wherein

Y is CR⁵ or N;

A is CH, CR⁴ or N;

n is 0, 1, 2, 3 or 4;

Q is -NR¹R² or when Y is CR⁵ then Q may also be hydrogen;

R¹ and R² are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C₁₋₆alkyl)amino, aryl and Het; or R¹ and R² taken together may form pyrrolidiny, piperidiny, morpholiny, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene;

Het is an aliphatic or aromatic heterocyclic radical, wherein said aliphatic heterocyclic radical is optionally substituted with an oxo group and wherein said aromatic heterocyclic radical is optionally substituted with hydroxy;

R^3 is hydrogen, aryl, C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyl substituted with C_{1-6} alkyloxy, C_{1-6} alkyl substituted with C_{1-6} alkyloxy; or

each R^4 independently is hydroxy, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy, or when Y is CR^5 then R^4 may also represent C_{1-6} alkyl substituted with cyano or aminocarbonyl;

R^5 is hydrogen or C_{1-4} alkyl;

L is $-X^1-R^6$ or $-X^2-Alk-R^7$, wherein

R^6 and R^7 each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxy, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is CR^5 then R^6 and R^7 may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethoxy and trihalomethyl; or when Y is N then R^6 and R^7 may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxy, formyl, cyano, nitro, amino, and trifluoromethyl;

X^1 and X^2 are each independently $-NR^3$ -, $-NH-NH$ -, $-N=N$ -, $-O$ -, $-S$ -, $-S(=O)$ - or $-S(=O)_2$;

Alk is C_{1-4} alkanedyl; or

when Y is CR^5 then L may also be selected from C_{1-10} alkyl, C_{3-10} alkenyl, C_{3-10} alkynyl, C_{3-7} cycloalkyl, or C_{1-10} alkyl substituted with one or two substituents independently selected from C_{3-7} cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five

substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆ alkyloxycarbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C₁₋₆alkylcarbonyl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro and trifluoromethyl; and

- (b) one or more pharmaceutically acceptable water-soluble polymers.
2. (Previously Presented) A particle according to claim 1 having a particle size of less than 1500 μm .
3. Canceled.
4. Canceled.
5. (Previously Presented) A particle consisting of a solid dispersion, comprising:
- (a) a compound selected from the group consisting of
 - 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 - 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; and
 - (b) one or more pharmaceutically acceptable water-soluble polymers.
6. (Previously Presented) A particle according to claim 1, wherein said compound (a) is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile.
7. (Previously Presented) A particle according to claim 1, wherein said water-soluble polymer is a polymer that has an apparent viscosity of 1 to 5000 mPa-s when dissolved at 20°C in an aqueous solution at 2% (w/v).

8. (Previously Presented) A particle according to claim 7, wherein the water-soluble polymer is a polymer selected from the group consisting of:

- alkylcelluloses,
- hydroxyalkylcelluloses,
- hydroxyalkyl alkylcelluloses,
- carboxyalkylcelluloses,
- alkali metal salts of carboxyalkylcelluloses,
- carboxyalkylalkylcelluloses,
- carboxyalkylcellulose esters,
- starches,
- pectines,
- chitin derivatives,
- di-, oligo- or polysaccharides,
- polyacrylic acids and the salts thereof,
- polymethacrylic acids, the salts and esters thereof, methacrylate copolymers,
- polyvinylalcohol, and
- polyalkylene oxides.

9. (Previously Presented) A particle according to claim 8, wherein said water-soluble polymer is hydroxypropyl methylcellulose.

10. (Previously Presented) A particle according to claim 9, wherein the weight ratio of (a):(b) is in the range of 1:1 to 1:899.

11. Canceled.

12. (Previously Presented) A particle according to claim 1, consisting of a solid solution, comprising:

- (a) two parts by weight of said compound (a); and
- (b) three parts by weight of hydroxypropyl methylcellulose.

13. (Previously Presented) A particle according to claim 1, further comprising one or more pharmaceutically acceptable excipients.

14. Canceled.

15. Canceled.

16. Canceled.

17. Canceled.

18. Canceled.

19. Canceled.

20. Canceled.

21. Canceled.

22. Canceled.

23. Canceled.

24. Canceled.

25. Canceled.

26. Canceled.


27. Canceled.

28. Canceled.

29. Canceled.

30. (Previously Presented) A solid dispersion comprising:

(a) a compound of formula



a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

Y is CR⁵ or N;

A is CH, CR⁴ or N;

n is 0, 1, 2, 3 or 4;

Q is $-\text{NR}^1\text{R}^2$ or when Y is CR^3 then Q may also be hydrogen;

R^1 and R^2 are each independently selected from hydrogen, hydroxy, C_{1-12} alkyl, C_{1-12} alkyloxy, C_{1-12} alkylcarbonyl, C_{1-12} alkyloxy carbonyl, aryl, amino, mono- or di(C_{1-12} alkyl)amino, mono- or di(C_{1-12} alkyl)aminocarbonyl wherein each of the aforementioned C_{1-12} alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C_{1-6} alkyloxy, hydroxy C_{1-6} alkyloxy, carboxyl, C_{1-6} alkyloxy carbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C_{1-6} alkyl)amino, aryl and Het; or

R^1 and R^2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C_{1-12} alkyl)amino C_{1-4} alkylidene;

R^3 is hydrogen, aryl, C_{1-6} alkylcarbonyl, C_{1-6} alkyl, C_{1-6} alkyloxy carbonyl, C_{1-6} alkyl substituted with C_{1-6} alkyloxy carbonyl; and

each R^4 independently is hydroxy, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, cyano, amino-carbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or when Y is CR^5 then R^4 may also represent C_{1-6} alkyl substituted with cyano or aminocarbonyl;

R^5 is hydrogen or C_{1-4} alkyl;

L is $-\text{X}^1-\text{R}^6$ or $-\text{X}^2-\text{Alk}-\text{R}^7$ wherein

R^6 and R^7 each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxy carbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is CR^5 then R^6 and R^7 may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then R^6 and R^7 may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxy carbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;

X^1 and X^2 are each independently $-\text{NR}^3$ -, $-\text{NH}-\text{NH}-$, $-\text{N}=\text{N}-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$ or $-\text{S}(=\text{O})_2-$;

Alk is C₁₋₄alkanediyl; or

when Y is CR⁵ then L may also be selected from C₁₋₁₀alkyl, C₃₋₁₀alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, or C₁₋₁₀alkyl substituted with one or two substituents independently selected from C₃₋₇cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, C₁₋₆alkyloxy carbonyl, formyl, nitro, amino, trihalomethyl, trihalomethoxy and C₁₋₆alkylcarbonyl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro and trifluoromethyl;

Het is an aliphatic or aromatic heterocyclic radical, wherein said aliphatic heterocyclic radical is optionally substituted with an oxo group and wherein said aromatic heterocyclic radical is optionally substituted with hydroxyl; and

(b) one or more pharmaceutically acceptable water-soluble polymers.

31. (Previously Presented) A solid dispersion according to claim 30, wherein the compound of formula (I-A) is a compound wherein Y is CR⁵ or N; A is CH, CR⁴ or N; n is 0, 1, 2, 3 or 4; Q is -NR¹R²; R¹ and R² are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxy carbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxy carbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C₁₋₆alkyl)amino, aryl and Het; or R¹ and R² taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₄alkylidene; R³ is hydrogen, aryl, C₁₋₆alkylcarbonyl, C₁₋₆alkyl, C₁₋₆alkyloxy carbonyl, C₁₋₆alkyl substituted with C₁₋₆alkyloxy carbonyl; each R⁴ independently is hydroxy, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethoxy; R⁵ is hydrogen or

C₁₋₄alkyl; L is -X¹-R⁶ or -X²-Alk-R⁷ wherein R⁶ and R⁷ each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl, X¹ and X² are each independently -NR³-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- or -S(=O)₂-, and Alk is C₁₋₄alkanediyl; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, cyano, nitro and trifluoromethyl; Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuran and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.

32. (Currently Amended) A solid dispersion according to claim 30, wherein the compound of formula (I-A) is selected from

4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile;
 6-[(2,6-dichlorophenyl)methyl]-N²-(4-fluorophenyl)-2,4-pyrimidinediamine;
 4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-acetamide;
 N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-butanamide;
 4-[[2-amino-6-(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile monohydrochloride;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]benzonitrile;
 N2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidinediamine;
 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dibromo-4-(1-methylethyl)phenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dichloro-4-(trifluoromethyl)phenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile;
 4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]benzeneacetoneitrile;
 4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;

4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitrile;
 4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide;
 4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile;
 4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl
 benzonitrile;
 4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-5-methyl-2-
 pyrimidinyl]amino]benzonitrile;
 4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-
 benzonitrile;
 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide, N3-oxide;
 N2-(4-chlorophenyl)-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine;
 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-
 pyrimidinyl]amino]benzonitrile;
 4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl
 benzonitrile;

4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile;
 4-[[4-amino-6-(2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2-chloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino] benzonitrile;
 4-[[4-(hydroxyamino)-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]-benzonitrile;
 4-[[4-amino-6-[(2-ethyl-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2,6-dichlorophenyl)thio]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenyl)amino]-1,3,5-triazin-2-yl]amino]-benzonitrile;
 4-[[4-amino-6-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-(hydroxyamino)-6-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-yl]amino]-benzonitrile;
 4-[[4-amino-6-[(2,4-dichloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]-benzonitrile;
 4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-6-(hydroxyamino)-1,3,5-triazin-2-yl]-amino]benzonitrile;
 4-[[4-(hydroxyamino)-6-(2,4,6-trichlorophenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile trifluoroacetate (1:1);
 4-[[4-(4-acetyl-2,6-dimethylphenoxy)-6-amino-1,3,5-triazin-2-yl]amino] benzonitrile;
 4-[[4-amino-6-(2,4,6-tribromophenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-(4-nitro-2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino] benzonitrile;
 4-[[4-amino-6-(2,6-dibromo-4-methylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-(4-formyl-2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2,4-dichlorophenyl)thio]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-[(5-acetyl-2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-6-amino-1,3,5-triazin-2-yl]amino]benzonitrile;

4-[[4-amino-6-[(4-bromo-2-chloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2-chloro-4,6-dimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[methyl(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[(2,6-dibromo-4-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 4-[[4-amino-6-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzonitrile;
 a *N*-oxide, or a pharmaceutically acceptable addition salt ~~or a stereochemically isomeric form~~ thereof.

33. (Currently Amended) A solid dispersion according to claim 32, wherein the compound of formula (I-A) is 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile; a *N*-oxide, or a pharmaceutically acceptable addition salt ~~or a stereochemically isomeric form~~ thereof.

34. (Currently Amended) A solid dispersion according to claim 32, wherein the compound of formula (I-A) is 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile; a *N*-oxide, or a pharmaceutically acceptable addition salt ~~or a stereochemically isomeric form~~ thereof.

35. (Previously Presented) A solid dispersion according to any one of claims 30-34, wherein the water-soluble polymer is a polymer that has an apparent viscosity of 1 to 5000 mPa.s when dissolved at 20°C in an aqueous solution at 2 % (w/v).

36. (Previously Presented) A solid dispersion according to any one of claims 30-34, wherein the water-soluble polymer is selected from the group comprising

- alkylcelluloses,
- hydroxyalkylcelluloses,
- hydroxyalkyl alkylcelluloses,
- carboxyalkylcelluloses,
- alkali metal salts of carboxyalkylcelluloses,
- carboxyalkylalkylcelluloses,
- carboxyalkylcellulose esters,
- starches,
- pectines,
- chitin derivatives ,
- di-, oligo- or polysaccharides,
- polyacrylic acids and the salts thereof,
- polymethacrylic acids, the salts and esters thereof, methacrylate copolymers,
- polyvinylalcohol,
- polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide.

37. (Previously Presented) A solid dispersion according to claim 36, wherein the water-soluble polymer is selected from the group comprising methylcellulose; hydroxymethylcellulose; hydroxyethylcellulose; hydroxypropylcellulose; hydroxybutylcellulose; hydroxyethyl methylcellulose; hydroxypropyl methylcellulose; carboxymethylcellulose; sodium carboxymethylcellulose; carboxymethylethylcellulose; sodium carboxymethylamyopectine; chitosan; trehalose; cyclodextrins or a derivative thereof; alginic acid, alkali metal and ammonium salts thereof; carrageenans; galactomannans; tragacanth; agar-agar; gummi arabicum; guar gummi; xanthan gummi; polyethylene oxide; polypropylene oxide; and copolymers of ethylene oxide and propylene oxide.

38. (Previously Presented) A solid dispersion according to claim 36, wherein the water-soluble polymer is selected from Eudragit E[®] and hydroxypropyl methylcellulose.

39. (Previously Presented) A solid dispersion according to any one of claim 36, wherein the water-soluble polymer is an aminoalkyl methacrylate copolymer.

40. (Previously Presented) A solid dispersion according to any one of claim 36, wherein the water-soluble polymer is hydroxypropyl methylcellulose.
41. (Previously Presented) A solid dispersion according to claim 40 wherein the hydroxypropyl methylcellulose has an apparent viscosity from about 1 to about 100 mPa.s when dissolved at 20°C in an aqueous solution at 2 % (w/v).
42. (Previously Presented) A solid dispersion according to claim 41, wherein the hydroxypropyl methylcellulose has an apparent viscosity from about 3 to about 15 mPa.s when dissolved at 20°C in an aqueous solution at 2 % (w/v).
43. (Previously Presented) A solid dispersion according to claim 42, wherein the hydroxypropyl methylcellulose has an apparent viscosity of about 5 mPa.s when dissolved at 20°C in an aqueous solution at 2 % (w/v).
44. (Previously Presented) A solid dispersion according to claim 43, wherein the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose HPMC 2910 5 mPa.s.
45. (Previously Presented) A solid dispersion according to 30, wherein the weight-by-weight ratio of (a) : (b) is in the range of 1 : 1 to 1 : 899.
46. (Previously Presented) A solid dispersion according to claim 45, wherein the weight-by-weight ratio of (a) : (b) is in the range of 1 : 1 to 1 : 100.
47. (Previously Presented) A solid dispersion according to claim 46, wherein the weight-by-weight ratio of (a) : (b) is in the range of 1 : 1 to 1 : 5.
48. (Previously Presented) A solid dispersion according to claim 47, wherein the weight-by-weight ratio of (a) : (b) is in the range of from about 1 : 1 to about 1 : 3.
49. (Previously Presented) A solid dispersion according to claim 47, wherein the weight-by-weight ratio of (a) : (b) is in the range of about 1 : 3 to about 1 : 5.

50. (Previously Presented) A solid dispersion according to claim 48 wherein the weight-by-weight ratio of (a) : (b) is in the range of about 1 : 1 to about 1 : 1.5.
51. (Previously Presented) A solid dispersion according to claim 48 wherein the weight-by-weight ratio of (a) : (b) is in the range of about 1 : 1.5 to about 1 : 3.
52. Canceled.